Exclusive: Following a severe setback, BridgeBio brings out the budget axe to chop staff but keeps quiet on the numbers
Three months after BridgeBio’s TTR amyloidosis candidate suffered a major — and according to CEO Neil Kumar, “baffling” — Phase III fail that wiped out $4 billion in market cap, Endpoints News has learned that the company is swinging the budget axe, all while lying low as best it can during the restructuring.
After receiving a call and tracking social media posts regarding a number of layoffs at BridgeBio, Kumar confirmed that the company has made cuts without specifying just how many.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.